
Breakthroughs that
See news releases about Etira, our stellar team,


Dr. Raj appointed as Etira Chief Medical Officer
NewsDallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…

First patient dosed in ERX-315-101 Clinical Trial
NewsSydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia.…

Drs. Jenkins and Stebbing join Etira Board
NewsDallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath,…

Validation of ERX-208 in Ovarian Cancer
NewsSeattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th…

ERX-315-001 SITE INITIATION VISIT @TKCC
NewsSydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…
Where to find us
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247